Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 16.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,843,632 shares of the company’s stock after purchasing an additional 554,185 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned 0.20% of Kenvue worth $82,753,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Empirical Finance LLC bought a new stake in shares of Kenvue during the 3rd quarter valued at $336,000. UniSuper Management Pty Ltd acquired a new position in shares of Kenvue during the 3rd quarter worth about $35,544,000. Howland Capital Management LLC acquired a new position in shares of Kenvue during the 3rd quarter worth about $7,764,000. Citizens Business Bank acquired a new position in shares of Kenvue during the 3rd quarter worth about $2,507,000. Finally, Fifth Third Bancorp raised its holdings in shares of Kenvue by 35.3% in the 4th quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock valued at $5,976,000 after purchasing an additional 72,435 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.
Kenvue Stock Up 0.8 %
Shares of KVUE stock opened at $19.27 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The firm’s 50 day moving average is $19.83 and its 200 day moving average is $20.17. Kenvue Inc. has a 12 month low of $17.82 and a 12 month high of $27.80.
Kenvue Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.15%. The ex-dividend date was Tuesday, February 13th.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on KVUE shares. JPMorgan Chase & Co. dropped their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. The Goldman Sachs Group initiated coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 target price on the stock. William Blair began coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating on the stock. Royal Bank of Canada cut their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Finally, Sanford C. Bernstein began coverage on shares of Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $24.85.
Read Our Latest Stock Report on KVUE
About Kenvue
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
- Five stocks we like better than Kenvue
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- United Airlines Soars on Earnings Beat
- 3 Warren Buffett Stocks to Buy Now
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Election Stocks: How Elections Affect the Stock Market
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.